ANP32C Antibody (Center) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | O43423 |
---|---|
Clone Names | 110726010 |
Other Names | Acidic leucine-rich nuclear phosphoprotein 32 family member C, Phosphoprotein 32-related protein 1, Tumorigenic protein pp32r1, ANP32C, PP32R1 |
---|---|
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | ANP32CP (HGNC:16675) |
---|---|
Synonyms | PP32R1 |
Tissue Location | Expressed in activated stem cells, such as mobilized CD34+ cells and cord blood CD34+ cells, but not in resting bone marrow CD34+ cells. Expressed in a variety of neoplastic cell lines, mainly in prostatic adenocarcinoma cell lines. Not expressed in normal prostatic tissue. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Phosphoprotein 32 (PP32) is a tumor suppressor that caninhibit several types of cancers, including prostate and breastcancers. The protein encoded by this gene is one of at least twoproteins that are similar in amino acid sequence to PP32 and arepart of the same acidic nuclear phosphoprotein gene family.However, unlike PP32, the encoded protein is tumorigenic. The tumorsuppressor function of PP32 has been localized to a 25 amino acidregion that is divergent between PP32 and the protein encoded bythis gene. This gene does not contain introns. [provided byRefSeq].
References
Matilla, A., et al. Cerebellum 4(1):7-18(2005)Kochevar, G.J., et al. Hum. Mutat. 23(6):546-551(2004)Fan, Z., et al. Nat. Immunol. 4(2):145-153(2003)Kadkol, S.S., et al. Breast Cancer Res. Treat. 68(1):65-73(2001)Kadkol, S.S., et al. Nat. Med. 5 (9), 1087 (1999) :
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.